erlotinib hydrochloride has been researched along with azacitidine in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (azacitidine) | Trials (azacitidine) | Recent Studies (post-2010) (azacitidine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 7,474 | 479 | 3,782 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | azacitidine (IC50) |
|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | 0.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C | 1 |
| Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A | 1 |
| Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E | 1 |
3 trial(s) available for erlotinib hydrochloride and azacitidine
| Article | Year |
|---|---|
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2014 |
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2014 |
1 other study(ies) available for erlotinib hydrochloride and azacitidine
| Article | Year |
|---|---|
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2013 |